New

ETF model portfolios designed for real investor needs. Discover →

Advertisement
Advertisement
Segment| Data as of 09/10/2026
trending down

Tomorrow's Treatments ETFs

1D perf
-1.78%
1D flows
-
Total AuM
$737M
Total ETFs
9

Aggregate data of 9 funds

Performance

-4.0-2.00.02.04.06.0%Aug 10Aug 17Aug 24Aug 31Sep 7

Flows

0 M10 M20 M30 M40 M
1M3MYTD1Y3Y5Y
Perf.-3.13%+16.18%+18.57%+53.34%+83.42%
Flows+$38M+$84M+$207M+$247M+$364M-

Top ETFs in this segment

1D-1.95%1W flows+$5MView
1D-2.61%1W flows-View
1D-0.96%1W flows-View
Advertisement

Just published in Tomorrow's Treatments

View all articles

Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities

Small-cap biotech ETFs focus on early-stage companies, offering explosive upside potential but higher risks compared to market-cap weighted competitors.

Biotech etfs

Movers in Tomorrow's Treatments

Top
Bottom
Top performers, 1 week1W perf.YTD perf.
ASD
Defiance Autism Impact ETF-3.48% 
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF-4.57%+2.46%
BBP
Virtus LifeSci Biotech Products ETF-4.73%+29.77%
THNR
Amplify Weight Loss Drug & Treatment ETF-5.11%+2.18%
SBIO
ALPS Medical Breakthroughs ETF-5.20%+24.90%
Top inflows, 1 week1W flowYTD flows
SBIO
ALPS Medical Breakthroughs ETF+$5M+$75M
BBC
Virtus LifeSci Biotech Clinical Trials ETF-+$5M
ASD
Defiance Autism Impact ETF--
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF--$2M
MEDX
Horizon Kinetics Medical ETF--$3M

Data period: September 3 - 10, 2026

Performance lists exclude leveraged and inverse ETFs

Recently launched ETFs

Inception

Related indexes by ICE

NYFSGIB
NYSE FactSet Global Genomics and Immuno Biopharma IndexView on ICE
NYFSNBM
NYSE FactSet Global Neuro Biopharma and MedTech IndexView on ICE

Latest news about Thematic Investing: Tomorrow's Treatments

Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities

Small-cap biotech ETFs focus on early-stage companies, offering explosive upside potential but higher risks compared to market-cap weighted competitors.

Biotech etfs

Obesity and Weight-Loss Drugs: A New Thematic ETF Segment?

The ongoing Ozempic and weight-loss drug obsession has investors and ETF issuers turning to new ways of gaining healthcare sector exposure.

Weight-loss-drugs

Two biotech ETFs to watch for the rest of 2022 and beyond

Investors with a high tolerance for risk may seek to gain exposure to the growth potential of the biotech industry. We take a look at two ETFs that have rallied over the last month.

Two biotech ETFs to watch for the rest of 2022 and beyond
Alan Joseph
By Alan Joseph · September 13, 2022
Advertisement
Advertisement
ETF U
Become a better investor with NYSE: The Home of ETFs
Visit the ETF U homepage
ETF Guides

Recent educational content

Tidal ETF Industry KPIs

ETF Trends

ETF Industry KPIs September 8, 2026

This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.

Tidal
By Tidal · September 9, 2026
Tidal ETF Industry KPIs

ETF Trends

ETF Industry KPIs August 31, 2026

This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.

Tidal
By Tidal · September 1, 2026
Tidal ETF Industry KPIs

ETF Trends

ETF Industry KPIs August 24, 2026

This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.

Tidal
By Tidal · August 24, 2026
What's the Fund | Ocean Park Diversified Income ETF (DUKZ)

What’sTheFund

What's the Fund | Ocean Park Diversified Income ETF (DUKZ)

James St Aubin, Chief Investment Officer at Ocean Park Asset Management, discuss the DUKZ ETF, exposing investors to the whole spectrum of asset classes in the fixed income markets, through their rules-based process.

NYSE logo
By NYSE · August 18, 2026

Browse all educational columns

ETF INVESTOR RESOURCES

Expert-Built ETF Portfolios, All in One Place

Don’t start from scratch. Discover ready-made ETF portfolios built by professionals to match different goals, timelines, and market views. Use them as inspiration or as a starting point for your own allocation.

Portfolio Builder